Compare Cytokinetics Inc (CYTK) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Fiverr International Ltd — how do they compare? Cytokinetics Inc trades at $62.89 (market cap $8.62B), while Fiverr International Ltd trades at $8.59 (market cap $310.61M). The key difference: Cytokinetics Inc is far larger — about 27.8× Fiverr International Ltd's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Fiverr International Ltd for 62 Days on average.
| CYTK | FVRR | |
|---|---|---|
Market Cap | $8.62B | $310.61M |
Volume | 2,594,626 | 381,459 |
Sector | Health | Media |
52-Week High | $87.26 | $23.60 |
52-Week Low | $54.76 | $8.47 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $8.72B | $63.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Fiverr International (FVRR) trades at $8.68, up 2.12% with bearish technical signals despite attractive valuation metrics including a P/E of 10.67 and P/S of 0.76. Recent earnings show mixed results with Q2 2026 missing estimates, while revenue growth has slowed from 2025's $431M to projected $418M in 2026. The company faces AI disruption pressures but maintains strong gross margins of 82% and positive net income.
The outlook remains cautious with analysts predominantly holding neutral ratings (76% Hold) and a $10.50 price target suggesting modest upside. Key risks include AI competition compressing freelance demand, while potential exists if Fiverr successfully adapts its platform to AI-driven market changes. Current valuation appears reasonable for patient investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
